ArticleJACC. Case reports2026
TTR Variant p.Ala65Val Causing Early-Onset Hereditary Transthyretin Amyloidosis With Mixed Cardiac and Neuropathic Phenotype.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVariant transthyretin amyloidosis (ATTRv) remains undercharacterized in Latin America, with limited awareness of its regional mutational diversity. CASE SUMMARY: A 48-year-old Peruvian man presented with syncope, exertional dyspnea, weight loss, and lower extremity paresthesia. Multimodality evaluation demonstrated severe infiltrative cardiomyopathy, small fiber and autonomic neuropathy, and peripheral nerve hypertrophy. Genetic testing identified a heterozygous pathogenic p.Ala65Val transthyretin variant, confirming ATTRv. No transthyretin-targeting therapies are currently accessible in Peru. DISCUSSION: To our knowledge, only 1 prior case harboring this variant has been reported, in a European patient with a late-onset presentation. Our patient exhibited an early-onset mixed cardiac and neuropathic phenotype, broadening the clinical spectrum of this rare variant. TAKE-HOME MESSAGE: This case highlights the phenotypic diversity of ATTRv and underscores the critical unmet need for disease-modifying therapy access and greater inclusion of Latin American patients in clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.